BridgeBio Pharma (BBIO, Financial) received a significant endorsement from Wolfe Research as the firm has initiated coverage on the stock with an "Outperform" rating. This development is anticipated to influence investor sentiment positively.
The analyst behind this coverage initiation, Andy Chen, has announced a price target of $49.00 USD for BridgeBio Pharma (BBIO, Financial). This suggests a confident outlook for the company's future market performance, aligning with the "Outperform" rating designation. The current price target indicates potential growth in the valuation of BBIO as viewed by Wolfe Research.
BridgeBio Pharma (BBIO, Financial) trades on the NASDAQ, and the recent analyst coverage could potentially stimulate interest and trading activity around the stock. Investors may watch the market closely following Wolfe Research's announcement to consider aligning their portfolios with the new insights provided.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 17 analysts, the average target price for BridgeBio Pharma Inc (BBIO, Financial) is $60.18 with a high estimate of $95.00 and a low estimate of $42.00. The average target implies an upside of 47.96% from the current price of $40.67. More detailed estimate data can be found on the BridgeBio Pharma Inc (BBIO) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, BridgeBio Pharma Inc's (BBIO, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for BridgeBio Pharma Inc (BBIO, Financial) in one year is $73.85, suggesting a upside of 81.58% from the current price of $40.67. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the BridgeBio Pharma Inc (BBIO) Summary page.
